OrSense to launch new non-invasive oximetry and hemoglobin monitor

According to OrSense, the NBM-200MP system offers for the first time a non-invasive, continuous and accurate measurement of oxygen saturation in states of hypovolemia, hypothermia and vasoconstriction or during open heart surgery, as well as during regular perfusion.

NBM-200MP is useful for hematocrit/hemoglobin determination, hidden blood loss monitoring and for anemia screening. The device is well suited for use in a variety of clinical environments, including perioperative and critical care, emergency medicine, blood donation facilities, women’s health, primary care physician’s office and homecare, the company said.

Lior Ma’ayan, CEO of OrSense, said: “Our novel non-invasive oximetry and hemoglobin monitor is expected to enhance the quality of treatment and reduce cost of operation in multiple hospital wards, with particular emphasis on the intensive care unit, operating room and emergency room. NBM-200MP addresses markets that represent annual revenue opportunities of over $2 billion.”